+ Watch BIIB
on My Watchlist
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.
A buyout? At a 33% premium to market, today's buyout price is $50 billion. Which pharma company has that much cash sitting around?
GlaxoSmithKlineBiogenIdec would be a good company name.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions